Please login to the form below

Not currently logged in
Email:
Password:

Lilly’s income drops 5 per cent

Eli Lilly & Company has reported a drop in net income of 5 per cent in the pharmaceutical company's financial results for the third quarter of 2011 due to increased operating expenses

Eli Lilly & Company has reported a drop in net income of 5 per cent in the pharmaceutical company's financial results for the third quarter of 2011.

The company made $1.24bn during the period in 2011 compared to $1.30bn in 2010.

In contrast, sales were up by 9 per cent to $6.15bn, despite antipsychotic Zyprexa (olanzapine) facing its first generic competition.

However, this improved revenue was cancelled out by operating expenses such as a $45m cost due to the mandatory pharmaceutical manufacturers fee associated with US healthcare reform, as well as a 13 per cent increase in marketing, selling and administrative expenses and a 5 per cent increase in R&D spending.

Lilly said this was mainly due to the recently-announced diabetes collaboration with Boehringer Ingelheim, which includes late-stage clinical trial costs.

Products that performed well included Cymbalta (duloxetine), which had a revenue increase of 29 per cent to make $1.07bn during the quarter due mainly to higher demand in international markets.

The insulin, Humalog, also achieved high growth, with revenue up 20 per cent.

Based on the company's performance, Lilly said it has updated certain elements of its 2011 financial guidance. It now expects full-year 2011 earnings per share to be in the range of $3.89 to $3.94.

20th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics